Replies to post #732616 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

its highly unusual for big pharma to make large deals with biotechs with unapproved drugs in the development stage. The risks are too big

Some Merck dev stage licensing deals in 2024:

LaNova just a few days ago up to $3B PD-L1/VEGF bispecific mab

EyeBio $1.3 up front and up to $3B tota

Curon Biopharmaceutical's CN201 for $700M up front plus up to $600M milestones

Modif. Preclinical GBM drug for 30m up front and up to $1.3B milestones

Harpoon - $680M Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager

I am fairly certain that in oncology the deals are usually prior to approval.

[manibiotech]

That's not accurate 

[Investor082]

You have no idea what you are talking about. Don’t be a bag holder, LP loves them!

[learningcurve2020]

Here I would've thought to get a jump on the competition that big pharma would've analysed a decade's worth of L Specials data to lock in a partnership.  Silly me.